Burgdorf, 20 December 2016, 7 a.m. – The human insulin of Russian pharmaceutical company GEROPHARM will in future be administered with a pen from Ypsomed's ServoPen® platform. This is a further confirmation of Ypsomed's platform strategy in the field of injection systems.
Burgdorf, 3 November 2016, 7:00 am – In the first half-year of the current business year 2016/17, the Ypsomed Group generated consolidated net sales of CHF 185.4 million, CHF 27.6 million more than compared with the same period of the previous year (CHF 157.8 million). This represents an increase in sales of 17.5%. In the first half-year of 2016/17, the operating result (EBIT) increased by an impressive 45.0% to CHF 28.1 million compared to the previous year. The EBIT margin is now at 15.2% (previous year: 12.3%). The increase in EBIT is largely due to higher sales and increased utilisation of production capacities, but also to efficiency improvements in production and sales processes. For the reporting period we can post a net profit of CHF 22.4 million.
Burgdorf, 19 October 2016, 7.00 a.m. – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine® Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen® platform, facilitates subcutaneous administration with its patient friendly design.
Michael Zaugg will join the Executive Management of the Ypsomed Group in mid-April 2017 and take on the role of Senior Vice President Human Resources. He will succeed Yvonne Müller, who is leaving Ypsomed at her own request.
The shareholders of Ypsomed Holding AG approved all proposals by the board of directors by a large majority at the regular general meeting held on 29 June 2016. For the past 2015/16 business year, a dividend of CHF 1.00 per share, exempt from withholding tax, will be paid to shareholders from reserves arising from capital contributions.
To deliver innovative care solutions, that improve the lives of people with diabetes, is the focus of the collaboration between Ypsomed and Novo Nordisk: Ypsomed’s own developed insulin pump mylife YpsoPump is fully compatible with NovoRapid PumpCart by Novo Nordisk.
What began by establishing the Décolletage AG company 100 years ago and was continued from 1994 as a company within the Disetronic/Ypsomed Group is now Ypsotec: an internationally operating and successful vendor in the fields of precision engineering and medical technology with over 160 employees in Europe. Ypsotec AG will be celebrating its long and successful company history at a number of events.
In the business year 2015/16, the Ypsomed Group generated consolidated sales totaling CHF 336.9 million (prior year: CHF 306.6 million). Compared with the previous year, this represents an increase in sales of 9.9%. The operating results (EBIT) also increased by 55.7% compared to the previous year, from CHF 28.5 million to CHF 44.4 million and lies considerably above the expectations of CHF 41 million. As a result, the profitability at the EBIT level lies at 13.2% (prior year: 9.3%) – despite the present currency exchange situation. For the current business year 2016/17, Ypsomed expects an accelerated growth in sales of around 12% and an EBIT of approximately CHF 55 million.
From March 2016 the Ypsomed Group will be gradually introducing the tubing free insulin patch pump mylife OmniPod for distribution via existing Group companies also in France, Finland, Denmark, Ireland and Luxembourg. In so doing Ypsomed is taking a considerable step towards expanding the growth basis of its diabetes supply business.
The reusable and affordable YpsoPen is becoming more and more popular. In the coming weeks, it will be supplied to Ukraine. The pharma company Indar, a private joint-stock company (PrJSC), is launching the insulin pen developed in Switzerland.